UK Pharmaceutical Supplier to India
India is the world's largest generic manufacturer, yet specific patient cases, rare diseases and novel biologics still require sourcing from the UK. The Central Drugs Standard Control Organization (CDSCO) regulates medicine import and grants named patient permission under Rule 36 of the New Drugs and Clinical Trials Rules. Euro Biom is an MHRA-licensed UK pharmaceutical supplier working with Indian tertiary hospitals, rare disease foundations and specialist clinics sourcing UK-origin branded, orphan, named patient and unregistered medicines. We hold WDA wholesale dealer authorisation, carry over 5,800 products in stock, and prepare every shipment with the documentation CDSCO and Indian customs actually look for.
Why Indian Hospitals and Rare Disease Foundations Struggle to Source UK Medicines
India manufactures most medicines it needs, but not all of them. When a treating physician in AIIMS, Tata Memorial or Apollo needs a UK-origin biologic, a rare disease orphan drug, or an unregistered specialty, sourcing becomes unexpectedly hard.
Rule 36 Named Patient Permission Is Specific
Under Rule 36 of the New Drugs and Clinical Trials Rules 2019, Indian treating physicians can apply to CDSCO for permission to import an unregistered medicine for a named patient. The application requires a UK supplier with traceable GMP provenance and GDP documentation. Most UK wholesalers cannot produce paperwork in the structure CDSCO accepts.
Rare Disease Medicines Have No Indian Manufacturer
For conditions like lysosomal storage disorders, PNH, hereditary angioedema and specific paediatric cancers, the treatment is a UK or European biologic with no Indian manufacturer. Indian rare disease foundations and the National Policy for Rare Diseases rely on import, which means a reliable UK supplier is essential, not optional.
CDSCO Documentation Standards Are Non-Negotiable
Indian customs at Mumbai, Delhi and Chennai reject consignments with incomplete or non-aligned paperwork every week. Certificate of Pharmaceutical Product, GMP, batch CoA, free sale certificate and GDP chain of custody must all be present and consistent. Most UK exporters underestimate what CDSCO actually checks.
Cold Chain Over a 9 Hour Direct Transit
Heathrow to Delhi or Mumbai is a 9 hour direct flight, often followed by customs delays of 24 to 72 hours. For biologics, oncology and gene therapies, temperature excursion risk over that full window is real. Standard freight forwarders do not plan for tarmac exposure in 40 degree Mumbai summers.
Urgent Oncology Requests Need Same-Day Response
When an Indian oncology patient's treatment pathway needs a UK-sourced medicine that is not available locally, the family and treating team need stock confirmation within hours. Most UK wholesalers send auto-acknowledgements and respond days later. That is not a clinical timeline.
Hospital Procurement Teams Need Single Accountability
Tertiary hospital pharmacy departments in India cannot manage five different wholesalers for one complex import. They need one UK counterparty who owns the shipment from Heathrow to Delhi, handles every certificate, and takes the call when Mumbai customs has a question at 2am IST.
An MHRA-Licensed UK Wholesaler Built for Indian Named Patient Supply
Importing a specialty medicine into India should be traceable, CDSCO-compliant and fast. Whether you are a consultant at a tertiary hospital sourcing a Rule 36 named patient medicine, a rare disease foundation coordinating a patient access programme, or a private clinic in Delhi managing a complex oncology case, we handle the UK side so your team can focus on the patient.
We hold MHRA Wholesale Dealer Authorisation WDA(H) 59239, stock over 5,800 medicines, and prepare every shipment with CDSCO-aligned documentation. Every Certificate of Pharmaceutical Product, batch CoA, free sale certificate and GDP record is structured to clear Delhi, Mumbai or Chennai customs without the back-and-forth most hospital buyers have grown used to.
Based at Heathrow, we dispatch via the direct Delhi and Mumbai air freight routes with temperature-validated containers and continuous monitoring. For Rule 36 named patient cases, we respond the same day and dispatch within 24 to 48 hours of CDSCO permission being confirmed.
Discuss Your RequirementsWhy Indian Hospital Buyers Choose Euro Biom
The practical reasons tertiary hospitals, rare disease foundations and specialty clinics across India work with us when they need UK-origin medicines.
Publicly Verifiable MHRA Licence
WDA(H) 59239 on the UK MHRA public register. Your procurement team verifies us in under a minute. No phantom wholesalers, no unverifiable credentials, no surprises when CDSCO asks to see supplier accreditation.
CDSCO-Aligned Export Documentation
Certificate of Pharmaceutical Product, Certificate of Free Sale, GMP certificates, batch-level Certificate of Analysis and GDP chain of custody, all prepared to the structure CDSCO and Indian customs officers actually check.
Rule 36 Named Patient Expertise
We understand exactly what Indian treating physicians and hospital pharmacies need on the UK side to support a Rule 36 application. Clean documentation, traceable manufacturer chain, immediate dispatch once permission is granted.
Rare Disease and Orphan Drug Sourcing
Active sourcing of UK and European orphan drugs for lysosomal storage disorders, hereditary angioedema, PNH and other rare conditions. We work with patient organisations and foundations to maintain compassionate access where possible.
We Hold Actual Stock
5,800+ pharmaceutical products in active UK warehouse stock. When we confirm availability for an Indian named patient case, the medicine is physically here and ready for dispatch, not a speculative supply chain promise.
Cold Chain to Delhi and Mumbai
Validated temperature-controlled containers for biologics, oncology and gene therapy products. Continuous monitoring Heathrow to destination, including planned tarmac exposure mitigation for Indian summer conditions.
Same-Day Response for Urgent Cases
When an Indian oncology or rare disease patient needs UK-sourced medicine urgently, we respond the same day with stock confirmation and dispatch within 24 to 48 hours. Human clinical timelines, not email-ticket timelines.
One Accountable Point of Contact
Single point of contact from first enquiry through to arrival at your hospital pharmacy in Delhi, Mumbai, Chennai or Bangalore. One email thread, complete visibility, no handoffs when Mumbai customs needs a clarification.
Pharmaceutical Supply Services for India
Four service lines built around the situations Indian tertiary hospitals, rare disease foundations and specialty clinics actually face when sourcing UK-origin medicines.
Rule 36 Named Patient Supply
For Indian treating physicians sourcing unregistered medicines under Rule 36 of the New Drugs and Clinical Trials Rules. We provide UK-side sourcing from verified GMP manufacturers, documentation structured for CDSCO, and immediate dispatch once permission is confirmed by Central Drugs Standard Control Organization.
- Rule 36 application documentation support
- UK GMP manufacturer sourcing with full provenance
- Oncology, rare disease, paediatric specialty products
- Same-day response for urgent cases
Rare Disease and Orphan Drug Supply
For Indian rare disease foundations, patient organisations and tertiary hospitals managing lysosomal storage disorders, hereditary angioedema, PNH, paediatric rare cancers and similar conditions. UK and European orphan drug sourcing with full GDP chain of custody and documentation ready for CDSCO.
- Orphan drug sourcing from UK and EU manufacturers
- Patient organisation collaboration
- Compassionate access programme support
- Full GDP-compliant documentation
Specialty Oncology and Biologic Supply
For Indian oncology centres and tertiary hospitals sourcing UK-origin biologics, targeted therapies and specialty oncology medicines not available through local channels. Temperature-validated cold chain to Delhi, Mumbai and Chennai with continuous monitoring throughout.
- Targeted therapies and biologic supply
- Validated cold chain to Indian hub airports
- CDSCO-aligned customs documentation
- Batch-level Certificate of Analysis provided
Hospital Procurement and Shortage Response
For Indian hospital pharmacy teams managing urgent shortages or specific import requirements where the UK is the only reliable source. Same-day stock confirmation, clean documentation, direct dispatch from our Heathrow facility without middlemen or reseller chains.
- Same-day stock confirmation
- Direct UK wholesaler supply, no middlemen
- Urgent shortage response
- Single accountable contact throughout
Trusted by Indian Hospital Buyers
Procurement teams and treating physicians at tertiary hospitals and rare disease foundations have chosen Euro Biom for UK-origin medicine supply to India.
"We needed an unregistered orphan drug for a paediatric lysosomal storage case. Euro Biom responded within hours, provided Rule 36 documentation exactly as CDSCO required, and the medicine cleared Delhi customs on the first attempt. That is rare."
"Their documentation standards match what our CDSCO team actually asks for. No back-and-forth, no resubmissions, no stuck consignments at Mumbai customs. That is worth more than price."
"For our rare disease patient access programme we needed a UK partner who understood orphan drug logistics and was willing to work case by case. Euro Biom does that, and their MHRA credentials are verifiable in a minute."
Our Process for Indian Pharmaceutical Supply
From first enquiry to arrival at your hospital pharmacy, the process is structured to be fast, traceable and clinically credible.
Step 1: Enquiry and Stock Confirmation
You send us the medicine name, strength, quantity and clinical context. We confirm UK stock availability the same day, quote price in GBP or USD, and outline the documentation we can provide for CDSCO or Rule 36 submission.
Step 2: Documentation Preparation
We prepare Certificate of Pharmaceutical Product, GMP certificates, batch-level Certificate of Analysis, Free Sale Certificate and GDP chain of custody, all structured for CDSCO and Indian customs clearance at Delhi, Mumbai or Chennai.
Step 3: Dispatch and Cold Chain
Once payment and import permission are confirmed, we dispatch from Heathrow via direct Delhi or Mumbai air freight. Temperature-sensitive products travel in validated containers with continuous monitoring and full chain of custody documentation.
Step 4: Customs Clearance and Delivery
We remain available throughout customs clearance to answer CDSCO or customs queries directly. Once cleared, onward delivery to your hospital pharmacy is coordinated with your chosen Indian logistics partner.
India Pharmaceutical Market Insight
The world's largest generic manufacturer still relies on imports for specific UK-origin branded and specialty medicines.
India's pharmaceutical market, the world's third largest by volume and valued at approximately USD 50 billion in 2024, is predominantly supplied by its massive domestic manufacturing sector, India produces over 60 percent of the world's vaccines and supplies approximately 20 percent of global generic medicine demand. However, for specific UK-origin branded medicines, advanced biologics, orphan drugs, and specialty products not manufactured in India, the country's hospitals and importers source from international markets including the UK. The Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health regulates pharmaceutical imports.
India's pharmaceutical import framework operates under the Drugs and Cosmetics Act 1940 and Rules 1945. For registered medicines, CDSCO marketing authorisation is required. For unregistered medicines needed for individual patients, India operates two relevant pathways: the personal import licence under Rule 68A (for individuals) and the hospital import pathway through the Drug Controller General of India (DCGI). Additionally, the Compassionate Use Programme allows specialist hospitals to import unapproved medicines for serious conditions. These pathways are used by major Indian hospital networks to source UK-origin medicines that are not available domestically.
India's private hospital sector, led by groups such as Apollo Hospitals, Fortis Healthcare, Max Healthcare, Manipal Hospitals, and Narayana Health, operates sophisticated pharmacy and import operations. These hospitals source UK-origin branded medicines for patients who specifically require or request them, particularly in oncology, immunology, and rare diseases. India's medical tourism sector, which attracts approximately 2 million international patients annually, also drives demand for UK and European-origin medicines that international patients expect.
Key therapeutic categories driving UK pharmaceutical imports to India include oncology (India's National Cancer Grid coordinates treatment across over 270 centres, with approximately 1.4 million new cancer cases annually), rare diseases (India's National Policy for Rare Diseases 2021 established treatment centres at eight Centres of Excellence), advanced biologics and biosimilars not yet manufactured domestically, and specialty dermatology and immunology products. The growing prevalence of non-communicable diseases, diabetes affects approximately 101 million Indians, hypertension approximately 315 million, is expanding demand for imported specialist medicines across all therapeutic areas.
Frequently Asked Questions About UK Medicine Supply to India
Practical questions from Indian hospital pharmacy teams, rare disease foundations and procurement managers, answered plainly.
Need a UK Pharmaceutical Supplier for India
Same-day response. MHRA-licensed. CDSCO-aligned documentation. Direct dispatch from Heathrow to Delhi, Mumbai, Chennai or Bangalore. Tell us the medicine, the patient context and the timeline. We will tell you within hours whether we can help.
MHRA WDA(H) 59239 · Company No. 15380737 · Registered England and Wales · work@eurobiom.co.uk